Q1 EPS Estimates for AngioDynamics Lowered by HC Wainwright

AngioDynamics, Inc. (NASDAQ:ANGO) – Equities research analysts at HC Wainwright dropped their Q1 2027 earnings per share estimates for shares of AngioDynamics in a research note issued on Wednesday, July 15th. HC Wainwright analyst Y. Chen now anticipates that the medical instruments supplier will post earnings of ($0.11) per share for the quarter, down from their prior forecast of ($0.05). HC Wainwright has a “Buy” rating and a $19.00 price target on the stock. The consensus estimate for AngioDynamics’ current full-year earnings is ($0.27) per share. HC Wainwright also issued estimates for AngioDynamics’ Q2 2027 earnings at ($0.10) EPS, Q3 2027 earnings at ($0.06) EPS and FY2027 earnings at ($0.27) EPS.

A number of other brokerages have also issued reports on ANGO. Canaccord Genuity Group raised their price objective on shares of AngioDynamics from $16.00 to $20.00 and gave the company a “buy” rating in a report on Wednesday. Zacks Research lowered shares of AngioDynamics from a “strong-buy” rating to a “hold” rating in a report on Monday, March 30th. Weiss Ratings restated a “sell (d-)” rating on shares of AngioDynamics in a research report on Monday, April 20th. Finally, Freedom Capital raised shares of AngioDynamics to a “strong-buy” rating in a research note on Monday, April 6th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, AngioDynamics has an average rating of “Moderate Buy” and a consensus target price of $19.50.

AngioDynamics Trading Down 4.5%

NASDAQ:ANGO opened at $13.51 on Friday. The stock’s 50-day moving average is $12.24 and its 200-day moving average is $11.35. AngioDynamics has a 1-year low of $8.36 and a 1-year high of $15.19. The stock has a market cap of $558.37 million, a P/E ratio of -15.53 and a beta of 0.34.

AngioDynamics (NASDAQ:ANGO) last posted its earnings results on Tuesday, July 14th. The medical instruments supplier reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.11) by $0.04. AngioDynamics had a negative return on equity of 5.73% and a negative net margin of 11.48%.The firm had revenue of $86.61 million during the quarter, compared to the consensus estimate of $80.24 million. AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS.

Institutional Investors Weigh In On AngioDynamics

Several institutional investors and hedge funds have recently made changes to their positions in ANGO. Kotler Kevin bought a new position in AngioDynamics during the fourth quarter worth $21,997,000. Weber Capital Management LLC ADV bought a new stake in AngioDynamics during the fourth quarter valued at $17,978,000. UBS Group AG boosted its position in AngioDynamics by 83.6% during the third quarter. UBS Group AG now owns 1,102,488 shares of the medical instruments supplier’s stock valued at $12,315,000 after acquiring an additional 501,881 shares during the last quarter. Millennium Management LLC grew its holdings in AngioDynamics by 28.1% during the 3rd quarter. Millennium Management LLC now owns 1,793,152 shares of the medical instruments supplier’s stock worth $20,030,000 after acquiring an additional 393,682 shares during the period. Finally, Nuveen LLC grew its holdings in AngioDynamics by 40.5% during the 4th quarter. Nuveen LLC now owns 1,295,072 shares of the medical instruments supplier’s stock worth $16,629,000 after acquiring an additional 373,110 shares during the period. Institutional investors and hedge funds own 89.43% of the company’s stock.

More AngioDynamics News

Here are the key news stories impacting AngioDynamics this week:

• Positive Sentiment: HC Wainwright reiterated a Buy rating on AngioDynamics and maintained a $19 price target, signaling confidence in the company’s longer-term upside despite ongoing losses. MarketBeat ANGO
• Positive Sentiment: An earlier report said AngioDynamics set a new 52-week high following an analyst upgrade, which likely reinforced bullish sentiment around the name. AngioDynamics Sets New 52-Week High Following Analyst Upgrade
• Neutral Sentiment: HC Wainwright cut several fiscal 2027 EPS estimates for AngioDynamics, including Q1, Q2, Q4, and full-year forecasts, reflecting a more cautious near-term earnings outlook. MarketBeat ANGO
• Neutral Sentiment: Despite the lower estimates, HC Wainwright still projects AngioDynamics will narrow losses over time, with FY2027 EPS estimated at ($0.27), close to the broader consensus of ($0.26). MarketBeat ANGO
• Negative Sentiment: A Seeking Alpha piece titled “AngioDynamics: Growth Is Working, Price Knows It (Rating Downgrade)” suggests some analysts see limited upside after the recent run, which could temper enthusiasm. Seeking Alpha article

About AngioDynamics

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.